Twist Bioscience Corp TWST
We take great care to ensure that the data presented and summarized in this overview for Twist Bioscience Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TWST
View all-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl6.94MShares$326 Million1.7% of portfolio
-
Black Rock Inc. New York, NY5.77MShares$271 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.46MShares$257 Million0.0% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.64MShares$218 Million0.25% of portfolio
-
Jpmorgan Chase & CO New York, NY3.61MShares$170 Million0.01% of portfolio
-
Nikko Asset Management Americas, Inc.3.55MShares$167 Million1.22% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.3.55MShares$167 Million0.08% of portfolio
-
William Blair Investment Management, LLC Chicago, IL3.51MShares$165 Million0.32% of portfolio
-
State Street Corp Boston, MA3.44MShares$162 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA2.46MShares$115 Million0.02% of portfolio
Latest Institutional Activity in TWST
Top Purchases
Top Sells
About TWST
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
Insider Transactions at TWST
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 03
2024
|
Patrick John Finn President and COO |
SELL
Open market or private sale
|
Direct |
2,311
-1.31%
|
$85,507
$37.13 P/Share
|
|
May 03
2024
|
Robert F. Werner Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
132
-0.3%
|
$4,884
$37.13 P/Share
|
|
May 03
2024
|
Emily M. Leproust Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,163
-0.81%
|
$154,031
$37.13 P/Share
|
|
May 03
2024
|
Paula Green SVP of Human Resources |
SELL
Open market or private sale
|
Direct |
910
-0.98%
|
$33,670
$37.13 P/Share
|
|
May 03
2024
|
Dennis Cho |
SELL
Open market or private sale
|
Direct |
568
-0.7%
|
$21,016
$37.13 P/Share
|
|
May 03
2024
|
William Banyai See Remark |
SELL
Open market or private sale
|
Direct |
798
-0.23%
|
$29,526
$37.13 P/Share
|
|
Apr 23
2024
|
Patrick John Finn President and COO |
SELL
Open market or private sale
|
Direct |
2,174
-1.22%
|
$65,220
$30.12 P/Share
|
|
Apr 09
2024
|
Adam Laponis Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
556
-0.74%
|
$18,348
$33.16 P/Share
|
|
Apr 02
2024
|
Paula Green SVP of Human Resources |
SELL
Open market or private sale
|
Direct |
229
-0.25%
|
$7,328
$32.74 P/Share
|
|
Apr 02
2024
|
Emily M. Leproust Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,132
-0.22%
|
$36,224
$32.74 P/Share
|
|
Apr 02
2024
|
Dennis Cho |
SELL
Open market or private sale
|
Direct |
129
-0.16%
|
$4,128
$32.74 P/Share
|
|
Apr 02
2024
|
William Banyai See Remark |
SELL
Open market or private sale
|
Direct |
327
-0.09%
|
$10,464
$32.74 P/Share
|
|
Apr 02
2024
|
Patrick John Finn President and COO |
SELL
Open market or private sale
|
Direct |
492
-0.28%
|
$15,744
$32.74 P/Share
|
|
Mar 20
2024
|
Paula Green SVP of Human Resources |
SELL
Open market or private sale
|
Direct |
200
-0.22%
|
$6,600
$33.52 P/Share
|
|
Mar 20
2024
|
Emily M. Leproust Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,128
-0.22%
|
$37,224
$33.52 P/Share
|
|
Mar 20
2024
|
William Banyai See Remark |
SELL
Open market or private sale
|
Direct |
442
-0.13%
|
$14,586
$33.52 P/Share
|
|
Mar 20
2024
|
Dennis Cho |
SELL
Open market or private sale
|
Direct |
230
-0.28%
|
$7,590
$33.52 P/Share
|
|
Mar 14
2024
|
Dennis Cho |
SELL
Open market or private sale
|
Direct |
93
-0.11%
|
$3,162
$34.6 P/Share
|
|
Mar 06
2024
|
William Banyai See Remark |
SELL
Open market or private sale
|
Direct |
549
-0.16%
|
$20,313
$37.43 P/Share
|
|
Mar 06
2024
|
Paula Green SVP of Human Resources |
SELL
Open market or private sale
|
Direct |
600
-0.64%
|
$22,200
$37.43 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 805K shares |
|---|---|
| Open market or private purchase | 10K shares |
| Exercise of conversion of derivative security | 13.3K shares |
| Payment of exercise price or tax liability | 83.3K shares |
|---|---|
| Open market or private sale | 23.2K shares |